Research programme: allergy immunotherapeutics - Sanofi

Drug Profile

Research programme: allergy immunotherapeutics - Sanofi

Alternative Names: Food allergy vaccine - Immune Design/Sanofi; Grass pollen allergy vaccine - Immune Design/Sanofi

Latest Information Update: 22 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sanofi
  • Developer Immune Design; Sanofi
  • Class Allergy immunotherapies; Food allergy immunotherapies
  • Mechanism of Action Immunomodulators; Toll-like receptor 4 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Food hypersensitivity; Hypersensitivity

Most Recent Events

  • 16 Mar 2016 Interim immunogenicity data in Hypersensitivity presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2016)
  • 27 Oct 2011 Early research in Hypersensitivity in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top